Healthcare Industry News: Urigen Pharmaceuticals
News Release - November 15, 2007
Urigen Pharmaceuticals, Inc. Provides Corporate Update
BURLINGAME, Calif.--(HSMN NewsFeed)--Urigen Pharmaceuticals, Inc., (OTCBB: URGP, www.urigen.com), a specialty pharmaceutical company focused on the development and commercialization of treatments for urological disorders, reports on its recent corporate developments. The company filed its Quarterly Report Form 10Q with the SEC on November 14, 2007.Urigen completed its reverse merger with Valentis, Inc. on July 13, 2007, which resulted in the company changing its name to Urigen Pharmaceuticals, Inc. One of the company’s first initiatives as a public company was to raise capital to advance the URG101 program for Painful Bladder Syndrome (PBS) and URG301 program for Overactive Bladder. Upon the completion of the merger, Urigen successfully completed a gross $2.1 million financing in July 2007.
During its first quarter as a public company, Urigen has continued to move forward with its clinical trials and development of therapeutic products for urological disorders. In August, the company initiated the URG101-104 Phase II Clinical Trial for PBS/Interstitial Cystitis.
“The depth and experience within our company provides the tools and expertise we need to become the preferred specialty pharmaceutical company in the area of Urology,” commented William Garner, M.D., Chief Executive Officer of Urigen. “Since completing the reverse merger in July of this year, we have remained focused on achieving our milestones and moving forward with clinical development.”
About Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen’s two lead programs target significant unmet medical needs and major market opportunities in urology. Urigen’s URG101 project targets painful bladder syndrome/interstitial cystitis, which affects approximately 10.5 million men and women in North America. Urigen’s URG301 project targets acute urgency in patients diagnosed with an overactive bladder, another major unmet need that is insufficiently managed by presently available overactive bladder drugs. URG301 is a proprietary dosage form of an approved drug that is locally delivered to control urinary urgency. For further information, please visit Urigen’s website at http://www.urigen.com.
Forward-Looking Statement
This press release may contain forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. For further risk factors associated with our Company, please review our SEC filings.
Source: Urigen Pharmaceuticals
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!